Patents by Inventor Vincenzo Summa

Vincenzo Summa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for preparing N-alkylated hydroxypyrimidinone compounds
    Patent number: 8357798
    Abstract: Potassium salts of Compound A and methods for their preparation are disclosed, wherein Compound A is of formula: Compound A is an HIV integrase inhibitor useful for treating or prophylaxis of HIV infection, for delaying the onset of AIDS, and for treating or prophylaxis of AIDS.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: January 22, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kevin M. Belyk, Henry G. Morrison, Philip Jones, Vincenzo Summa, V. Brett Cooper, Amar J. Mahajan, Daniel J. Kumke, Hsien-Hsin Tung, Lawrence Wai, Vanessa Pruzinsky, Philip Pye, Remy Angelaud, Danny Mancheno
  • Macrocyclic compounds as antiviral agents
    Patent number: 8314062
    Abstract: The present invention relates to macrocyclic compounds of formula (I): wherein W, n, m, R1, R2, R3, R4, R5, Ra, M, Z and ring B are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: November 20, 2012
    Assignee: Instituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Benedetta Crescenzi, Monica Donghi, Marco Ferrara, Cristina Gardelli, Steven Harper, Uwe Koch, Michael Rowley, Vincenzo Summa
  • Nucleoside derivatives as inhibitors of viral polymerases
    Patent number: 8183216
    Abstract: A class of nucleoside derivatives of formula (I), as defined herein, that are useful as inhibitors of RNA-dependent RNA viral replication and in particular HCV replication, are provided. Also provided are processes for the synthesis and use of such compounds for treating or preventing HCV infection. formula (I).
    Type: Grant
    Filed: September 16, 2008
    Date of Patent: May 22, 2012
    Assignee: Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Maria Emilia Di Francesco, Vincenzo Summa, Gabriella Dessole
  • Macrocyclic compounds as antiviral agents
    Patent number: 8178520
    Abstract: The present invention relates to macrocyclic compounds of formula (I): wherein W, n, R1, Ra, Rb, R3, R4, M, Z, ring A and ring B are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: May 15, 2012
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA
    Inventors: Maria Emilia Di Francesco, Emanuela Nizi, Paola Pace, Vincenzo Summa
  • HCV NS3 protease inhibitors
    Patent number: 8138164
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: March 20, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Nigel J. Liverton, Vincenzo Summa, Joseph P. Vacca
  • Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
    Patent number: 8080654
    Abstract: The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: December 20, 2011
    Assignees: Insituto di Ricerche di Biologia Molecolare P. Angeletti SpA, Merck Sharp & Dohme Corp.
    Inventors: Steven Harper, Vincenzo Summa, Nigel J. Liverton, John A. McCauley
  • NUCLEOSIDE DERIVATIVES AS INHIBITORS OF VIRAL POLYMERASES
    Publication number: 20110306573
    Abstract: Compounds of structural formula (I): and pharmaceutically acceptable salts thereof; wherein R1; R2; R3; Q1 and Q2 are as defined herein, processes for their preparation; pharmaceutical compositions containing them and their use in medicine, in particular the treatment or prevention of HCV infections, are disclosed.
    Type: Application
    Filed: September 2, 2009
    Publication date: December 15, 2011
    Inventors: Salvatore Avolio, Maria Emilia Di Francesco, Marco Pompei, Vincenzo Summa
  • HIV INTEGRASE INHIBITORS
    Publication number: 20110257162
    Abstract: Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein m, n, X, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: June 29, 2011
    Publication date: October 20, 2011
    Inventors: Vincenzo Summa, Paola Pace, Philip Jones, Alessia Petrocchi, Maria del Rosario Rico Ferreira, Giuseppe Cecere
  • MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS
    Publication number: 20110224134
    Abstract: The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.
    Type: Application
    Filed: May 20, 2011
    Publication date: September 15, 2011
    Applicants: Istituto Di Ricerche Di Biologia Molecolare P. Angeletti SPA, Merck Sharp & Dohme Corp.
    Inventors: Steven Harper, Vincenzo Summa, Nigel J. Liverton, John A. McCauley
  • HIV integrase inhibitors
    Patent number: 7981879
    Abstract: Compounds of Formula I are inhibitors of FHV integrase and inhibitors of FHV replication (I), wherein m, n, X, R1, R2, R3, R4, R5, R6, R7; R8, R9 and R10 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HTV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HTV infection and ADDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: July 19, 2011
    Assignee: Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Vincenzo Summa, Paola Pace
  • Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
    Patent number: 7973040
    Abstract: The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: July 5, 2011
    Assignees: Merck Sharp & Dohme Corp., Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA
    Inventors: Steven Harper, Vincenzo Summa, Nigel J. Liverton, John A. McCauley
  • Tetrahydro-4H-pyrido[1,2-a] pyrimidines useful as HIV integrase inhibitors
    Patent number: 7968553
    Abstract: Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds of Formula A: are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein n is an integer equal to zero, 1, 2 or 3, and R1, R3, R4, R12, R14, R16, R30, R32, R34 and R36 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: June 28, 2011
    Assignee: Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Benedetta Crescenzi, Olaf Kinzel, Ester Muraglia, Federica Orvieto, Giovanna Pescatore, Michael Rowley, Vincenzo Summa
  • HIV integrase inhibitors
    Patent number: 7939537
    Abstract: Pyridopyrimidine carboxamide compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein R1, R2, R3, R4, R5 and R6 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: May 10, 2011
    Assignee: Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Vincenzo Summa, Olaf Kinzel, Monica Donghi
  • N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE
    Publication number: 20110034449
    Abstract: N-substituted 5-hydroxypyrimidin-6-one-4-carboxamides of formula: are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R1, R2, R3 and R4 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Application
    Filed: September 17, 2010
    Publication date: February 10, 2011
    Applicant: Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA
    Inventors: Benedetta Crescenzi, Cristina Gardelli, Ester Muraglia, Emanuela Nizi, Federica Orvieto, Paola Pace, Giovanna Pescatore, Alessia Petrocchi, Marco Poma, Michael Rowley, Rita Scarpelli, Vincenzo Summa
  • HCV NS3 Protease Inhibitors
    Publication number: 20100317623
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: October 19, 2007
    Publication date: December 16, 2010
    Inventors: Nigel J. Liverton, Vincenzo Summa, Joseph P. Vacca
  • HCV NS3 Protease Inhibitors
    Publication number: 20100298210
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use treating or preventing HCV infections.
    Type: Application
    Filed: October 19, 2007
    Publication date: November 25, 2010
    Inventors: Nigel J. Liverton, Vincenzo Summa, Joseph P. Vacca, Maria Emilia Di Francesco, Marco Pompei
  • N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
    Patent number: 7820660
    Abstract: N-substituted 5-hydroxypyrimidin-6-one-4-carboxamides of formula: are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R1, R2, R3 and R4 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: October 26, 2010
    Assignee: Instituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Benedetta Crescenzi, Cristina Gardelli, Ester Muraglia, Emanuela Nizi, Federica Orvieto, Paola Pace, Giovanna Pescatore, Alessia Petrocchi, Marco Poma, Michael Rowley, Rita Scarpelli, Vincenzo Summa
  • Nucleoside Derivatives as Inhibitors of Viral Polymerases
    Publication number: 20100210581
    Abstract: A class of nucleoside derivatives of formula (I), as defined herein, that are useful as inhibitors of RNA-dependent RNA viral replication and in particular HCV replication, are provided. Also provided are processes for the synthesis and use of such compounds for treating or preventing HCV infection.
    Type: Application
    Filed: September 16, 2008
    Publication date: August 19, 2010
    Applicant: Istitute de Ricerche di Biologia Molecolare P. Angeletti
    Inventors: Maria Emilia Di Francesco, Vincenzo Summa, Gabriella Dessole
  • Macrocyclic Compounds As Antiviral Agents
    Publication number: 20100183551
    Abstract: A class of macrocyclic compounds of formula (I), wherein R1, R3, R4, Ra, Rb, A, Z, Y, X, M, W, n and m are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes 5 for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.
    Type: Application
    Filed: July 17, 2008
    Publication date: July 22, 2010
    Inventors: Steven Harper, Vincenzo Summa, Nigel J. Liverton, John A. McCauley, John W. Butcher, Marcello Di Filippo, Maria Emilia Di Francesco, Marco Ferrara, Joseph J. Romano, Michael T. Rudd
  • HCV NS3 Protease Inhibitors
    Publication number: 20100099695
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: October 23, 2007
    Publication date: April 22, 2010
    Inventors: Nigel J. Liverton, Vincenzo Summa, Maria Emilia Di Francesco, Marco Ferrara, Kevin F. Gilbert, Steven Harper, John A. McCauley, Charles A. McIntyre, Alessia Petrocchi, Marco Pompei, Joseph J. Romano, Michael T. Rudd, John W. Butcher, M. Katharine Holloway